卵巢癌诊断市场规模、份额、成长分析，按癌症类型、测试类型、地区划分 - 产业预测，2025-2032 年

卵巢癌诊断的全球市场规模预计在2023 年达到19 亿美元，从2024 年的20 亿美元增长到2032 年的30.5 亿美元，预计在预测期内（2025-2032 年）复合年增长率为5.4% 。

卵巢癌，尤其是上皮性卵巢癌，是一个严重的健康问题，是全球女性癌症相关死亡的第五大原因。卵巢癌诊断市场的快速成长是由多种因素推动的，包括创新治疗方法、癌症研究资金的增加、健康意识的提高以及老年女性人口的增加。诊断技术的进步为加强早期检测提供了新的机会。目前，现有方法存在显着差距，往往只能在晚期阶段才能识别出疾病。此外，政府和机构努力开发方便、及时的诊断解决方案对于市场成长也至关重要。这样的生态系凸显了卵巢癌早期检测和显着改善治疗结果的潜力。

目录

介绍

• 研究目的
• 调查范围
• 定义

调查方法

• 资讯采购
• 二手资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 抑制因素和挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 价格分析
• 监管分析
• 案例研究分析

卵巢癌诊断市场规模：依癌症类型划分

• 市场概况
• 上皮性肿瘤的诊断
• 生殖细胞癌的肿瘤诊断
• 间质癌的肿瘤诊断
• 其他的

卵巢癌诊断市场规模：依测试类型

• 市场概况
• 影像
  • 超音波
• 电脑断层扫描
• 核磁共振扫描
• 正子断层扫描
  • 其他的
• 验血
• CA125
• HER2
• BRCA
• 印度核能管理局
• 急诊室及公关
• KRAS突变
  • 其他的
• 切片检查
• 其他的

卵巢癌诊断市场规模：依最终用户划分

• 市场概况
• 医院相关实验室
• 独立诊断实验室
• 癌症研究组织
• 其他的

卵巢癌诊断市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东/非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争资讯

• 前5名企业对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分類的份额分析
• 收益与前一年同期比较（2022-2024）

主要企业简介

• Illumina
• Thermo Fisher Scientific
• Roche
• Siemens Healthineers
• Abbott
• QIAGEN
• Hologic
• Beckman Coulter
• Becton, Dickinson and Company（BD）
• Bio-Rad Laboratories
• Quest Diagnostics
• Myriad Genetics
• Genomic Health（Exact Sciences）
• Agilent Technologies
• PerkinElmer Inc.
• bioMerieux SA
• Merck KGaA
• GE Healthcare
• Sysmex Corporation
• NanoString Technologies

结论和建议

Global Ovarian Cancer Diagnostic Market size was valued at USD 1.9 billion in 2023 and is poised to grow from USD 2 billion in 2024 to USD 3.05 billion by 2032, growing at a CAGR of 5.4% during the forecast period (2025-2032).

Ovarian cancer, particularly epithelial ovarian cancer, is a significant health concern and the fifth leading cause of cancer-related death among women globally. The surge in the ovarian cancer diagnostics market is driven by several factors, including innovative treatment modalities, increased funding for cancer research, heightened health awareness, and a growing population of older women. Advancements in diagnostic technologies present new opportunities to enhance early detection, currently a major gap in existing methods that tend to identify the disease only at advanced stages. Additionally, government and institutional efforts to develop convenient and timely diagnostic solutions are crucial for market growth. This ecosystem underscores the potential for significant improvements in early detection and treatment outcomes in the ovarian cancer landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Ovarian Cancer Diagnostic market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Ovarian Cancer Diagnostic Market Segmental Analysis

Global Ovarian Cancer Diagnostic Market is segmented by cancer type, test type, end user and region. Based on cancer type, the market is segmented into epithelial tumor diagnostics, germ cell carcinoma tumor diagnostics, stromal carcinoma tumor diagnostics and others. Based on test type, the market is segmented into imaging, blood test, biopsy and others. Based on end user, the market is segmented into hospital associated labs, independent diagnostic laboratories, cancer research institutes and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Ovarian Cancer Diagnostic Market

The Global Ovarian Cancer Diagnostic market is being significantly propelled by the increasing population of elderly women, which correlates with a higher incidence of ovarian cancer cases. This demographic shift is prompting governments to enhance healthcare initiatives aimed at cancer detection and treatment. Moreover, rising healthcare awareness among individuals is contributing to market expansion, as more patients seek diagnostic solutions and innovative treatments, including established drugs like Bevacizumab (Avastin) and Pazopanib (Votrient). Concurrently, the expiration of patents for existing medications is paving the way for new entrants into the market and stimulating the adoption of innovative combination therapies. Additionally, ongoing research and development, supported by both governmental and private funding, further enrich the market landscape, creating opportunities for advancements in ovarian cancer diagnostics and treatments.

Restraints in the Global Ovarian Cancer Diagnostic Market

One significant restraint affecting the global ovarian cancer diagnostic market is the widespread ignorance surrounding the symptoms of ovarian cancer. Often, these symptoms are overlooked or misdiagnosed, as they can easily be mistaken for those associated with other medical conditions. This lack of awareness leads to delayed detection and diagnosis, severely impacting treatment outcomes. As a result, the progression of ovarian cancer can worsen, complicating the clinical management of the disease. Ultimately, this scenario not only hinders patient outcomes but also impacts market growth, as timely diagnosis and treatment are crucial for effective management of ovarian cancer.

Market Trends of the Global Ovarian Cancer Diagnostic Market

The global ovarian cancer diagnostic market is witnessing a significant upward trend driven by the growing understanding of cancer biomarkers and advancements in detection technologies. Enhanced biotechnological innovations have facilitated the identification and commercialization of potential biomarkers, creating new avenues for effective diagnosis and treatment of ovarian cancer. This surge in biomarker research, coupled with improved diagnostic equipment, is empowering healthcare providers with tools for early detection, thus enhancing patient outcomes. As a result, the market is poised for substantial growth as stakeholders invest in the development and implementation of novel diagnostic solutions to meet the rising demand for precision oncology.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis
• Case Study Analysis

Global Ovarian Cancer Diagnostic Market Size by Cancer Type & CAGR (2025-2032)

• Market Overview
• Epithelial Tumor Diagnostics
• Germ Cell Carcinoma Tumor Diagnostics
• Stromal Carcinoma Tumor Diagnostics
• Others

Global Ovarian Cancer Diagnostic Market Size by Test Type & CAGR (2025-2032)

• Market Overview
• Imaging
  • Ultrasound
• CT Scan
• MRI Scan
• PET Scan
  • Others
• Blood Test
• CA125
• HER2
• BRCA
• CEA
• ER & PR
• KRAS Mutation
  • Others
• Biopsy
• Others

Global Ovarian Cancer Diagnostic Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospital Associated Labs
• Independent Diagnostic Laboratories
• Cancer Research Institutes
• Others

Global Ovarian Cancer Diagnostic Market Size & CAGR (2025-2032)

• North America (Cancer Type, Test Type, End User)
  • US
  • Canada
• Europe (Cancer Type, Test Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Cancer Type, Test Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Cancer Type, Test Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Cancer Type, Test Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
• Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Illumina
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hologic
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beckman Coulter
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (BD)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quest Diagnostics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genomic Health (Exact Sciences)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bioMerieux SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE Healthcare
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NanoString Technologies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations